| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5661537 | Pancreatology | 2017 | 4 Pages |
Abstract
Median OS observed in the elderly was similar to OS previously reported in younger patients in the ACCORD 11 trial. FOLFIRINOX is effective in selected, fit elderly patients but with greater grade 3 neurotoxicity. Primary dose reduction and primary GCSF prophylaxis may control tolerance.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
C. Baldini, A. Escande, O. Bouché, F. El Hajbi, J. Volet, V. Bourgeois, T. Renaut Vantroys, A. Ploquin, C. Desauw, M. Hebbar,